You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Sage Therapeutics secures $20m to accelerate development of drugs to treat central nervous system diseases

Continue reading below

Sage Therapeutics, a Cambridge-based biopharmaceutical company developing medicines to treat central nervous system diseases, announced Wednesday a $20 million Series B financing from investors Arch Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011.

Robert Nelsen, cofounder and managing director of Arch Ventures, will join the Sage board of directors, the company said in a press release.

According to Nelsen, Sage’s “approach to restoring the natural balance of brain activity has the potential to address a number of debilitating CNS disorders, including traumatic brain injury, Fragile X, depression, and pain, where there is a dire need for better therapies.”

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.